Bluejay’s lead product candidate brelovitug (BJT-778) recently received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation for the treatment of chronic hepatitis delta (CHD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback